These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10940280)

  • 1. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
    Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
    Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
    Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
    Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
    Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
    Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
    D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
    World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
    Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
    Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
    Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
    Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
    J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
    Zezos P; Patsiaoura K; Nakos A; Mpoumponaris A; Vassiliadis T; Giouleme O; Pitiakoudis M; Kouklakis G; Evgenidis N
    Colorectal Dis; 2014 Dec; 16(12):O420-30. PubMed ID: 25040651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis.
    Odze R; Antonioli D; Peppercorn M; Goldman H
    Am J Surg Pathol; 1993 Sep; 17(9):869-75. PubMed ID: 8352372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
    van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
    Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
    Lichtenstein GR; Kamm MA
    Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
    Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
    [No Abstract]   [Full Text] [Related]  

  • 15. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
    Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
    Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
    Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
    Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity.
    Pearl DS; Shah K; Whittaker MA; Nitch-Smith H; Brown JF; Shute JK; Trebble TM
    J Crohns Colitis; 2013 Jul; 7(6):481-9. PubMed ID: 22974822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
    Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
    Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of OATP2B1 by proinflammatory cytokines leads to 5-ASA hyposensitivity in Ulcerative colitis.
    Li P; Luo J; Jiang Y; Pan X; Dong M; Chen B; Wang J; Zhou H; Jiang H; Duan Y; Lin N
    Chem Biol Interact; 2024 Aug; 398():111074. PubMed ID: 38844255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
    Tang H; Xiang D; Wang F; Mao J; Tan X; Wang Y
    Mol Med Rep; 2017 Mar; 15(3):1117-1122. PubMed ID: 28138699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.